RealGiDo - Real-world study on dose adjustment

Document ID: PC-PH-100404

01/11/2018

Author: Boehringer Ingelheim


RealGiDo, a global study across 13 countries, confirmed that dose adjustment is effective to help manage side effects, without compromising efficacy.
Disclaimer: The standard Afatinib (Giotrif®) dose is 40 mg/day.

123,000
Views

100k 340

References & Footnote:

1. Sequist LV et al. J Clin Oncol. 2013;31(27):3327-3334.
2. Wu YL et al. Lancet Oncol. 2014;15(2):213-22.
3. Yang JC et al. Lancet Oncol. 2015;16(2):141-51.
4. Park K et al. Abstract LBA2 and oral presentation. European Society for Medical Oncology (ESMO) ASIA, Singapore, 20th December 2015.

EGFR M+=epidermal growth factor receptor mutation positive; NSCLC=non-small cell lung cancer; PFS=progression-free survival; OS=overall survival.
* LUX-Lung 3 (vs pemetrexed/cisplatin) and LUX-Lung 6 (vs gemcitabine/cisplatin): superior PFS (primary endpoint) and superior OS in Del19 subgroup (secondary endpoint); LUX-Lung 7 (vs gefitinib): superior PFS (primary endpoint).

RELATED CONTENT

 
MPR-PH-100073
Production date: Nov 2018

What is Afatinib (Giotrif®)?

Afatinib (Giotrif®) is an irreversible ErbB Family blocker approved in more than 70 markets. It is indicated for the treatment of patients with distinct types of epidermal growth factor receptor EGFR mutation-positive (EFGR M+) locally advanced or metastatic non-small cell lung cancer (NSCLC), and for the treatment of patients with locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy. It is an oral, once-daily, targeted therapy.[1]

*Afatinib is approved in more than 70 markets including the EU, Japan, Taiwan, and Canada under the brand name Giotrif®, in the US under the brand name Giotrif® and in India under the brand name Xovoltib®
 

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about Afatinib (Giotrif®)?

The side effects of Afatinib are predictable, generally manageable and reversible. In studies to date, drug-related adverse events (AEs) were largely related to the gastrointestinal tract (diarrhoea) and skin disorders (rash), which is in line with EGFR tyrosine kinase inhibition.[1-4] For further details, please refer to the prescribing information.

References:
[1] GIOTRIF® Summary of Product Characteristics 2018
[2] Sequist L et al. J Clin Oncol 2013;31(27)3327–34.
[3] Wu YL et al. Lancet Oncol 2014;15(2):213–22.
[4] Park K et al. Lancet Oncol 2016;17(5):577–89.